1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay.
Saved in:
| Title: | 1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. |
|---|---|
| Authors: | Fong, C.Y.K.1 (AUTHOR), Iyer, S.2 (AUTHOR), Potts, L.3 (AUTHOR), Peckitt, C.3 (AUTHOR), Cromarty, S.1 (AUTHOR), Saffery, C.1 (AUTHOR), Kidd, S.1 (AUTHOR), Rana, T.1 (AUTHOR), Ausec, L.4 (AUTHOR), Gregorc, A.4 (AUTHOR), Pointing, D.4 (AUTHOR), Gombert, M.5 (AUTHOR), von Loga, K.6 (AUTHOR), Benjamin, L.7 (AUTHOR), Starling, N.1 (AUTHOR), Waddell, T.S.8 (AUTHOR), Petty, R.9 (AUTHOR), Uhlik, M.2 (AUTHOR), Chau, I.1 (AUTHOR), Cunningham, D.1 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1110-S1110. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.1344 |
